Xuenong Ouyang
Overview
Explore the profile of Xuenong Ouyang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1043
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shi Y, Li J, Xu J, Sun Y, Wang L, Cheng Y, et al.
Cancer Commun (Lond)
. 2019 May;
39(1):28.
PMID: 31126331
Background: The 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic colorectal cancer (mCRC), however, the optimal second-line regimen for KRAS wild-type mCRC patients is still investigational....
2.
Qin S, Li J, Wang L, Xu J, Cheng Y, Bai Y, et al.
J Clin Oncol
. 2018 Sep;
36(30):3031-3039.
PMID: 30199311
Purpose: Cetuximab in combination with chemotherapy is a standard-of-care first-line treatment regimen for patients with wild-type (wt) metastatic colorectal cancer (mCRC); however, the efficacy of cetuximab plus leucovorin, fluorouracil, and...
3.
Lin Y, Wang X, Yu Y, Liu W, Xie F, Ouyang X, et al.
Oncol Lett
. 2018 Jan;
14(6):7473-7482.
PMID: 29344191
Cyclin-dependent kinase inhibitor 1A (CDKN1A) is an important cell cycleregulator, and has been identified to exhibit aberrant expression in various types of cancer tissues. However, the association between CDKN1A expression...
4.
Ouyang X, Shi M, Jie F, Bai Y, Shen P, Yu Z, et al.
Invest New Drugs
. 2017 Nov;
36(2):315-322.
PMID: 29134432
Background Dulanermin is a recombinant soluble human Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that activates apoptotic pathways by binding to proapoptotic death receptor (DR) 4 and DR5. The purpose...
5.
Huang Y, Zheng J, Tan T, Song L, Huang S, Zhang Y, et al.
Int J Biol Markers
. 2017 Oct;
33(2):189-194.
PMID: 29076521
Objective: BTG1 is a member of the TOB/BTG protein family, which is a transducer of ErbB-2 and TOB2. It is known to inhibit tumor genesis, but its role in pancreatic...
6.
Yin Y, Zhu X, Huang S, Zheng J, Zhang M, Kong W, et al.
Tumour Biol
. 2017 Jun;
39(6):1010428317699131.
PMID: 28618924
The limited efficacy of conventional therapies for pancreatic ductal adenocarcinoma has led to the growing interest for identifying potential antigenic targets for immunotherapy. Placenta-specific 1 (PLAC1) is a new member...
7.
Yu R, Li C, Lin X, Chen Q, Li J, Song L, et al.
Pathol Res Pract
. 2017 Jun;
213(8):964-968.
PMID: 28559119
MYBL2 (B-MYB), a member of the MYB family of transcription factor genes, regulates the expression of genes in the process of tumorigenesis. Many studies have shown that MYBL2 is high...
8.
Sun Y, Shu Y, Liu B, Liu P, Wu C, Zheng R, et al.
Exp Ther Med
. 2017 Jan;
12(6):4017-4024.
PMID: 28105133
The present study aimed to evaluate the efficacy and safety of acetyl-L-carnitine (ALC) for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). The study was carried out as a prospective, randomized,...
9.
Wu J, Song Y, Su L, Xu L, Chen T, Zhao Z, et al.
BMC Cancer
. 2016 Jul;
16:537.
PMID: 27460571
Background: The efficacy and safety of rituximab-based chemotherapy (R-chemo), the standard regimen for patients with diffuse large B-cell lymphoma (DLBCL), which is more common in Asia than in Western countries,...
10.
Zhang X, Lv L, Ouyang X, Zhang S, Fang J, Cai L, et al.
Cancer Med
. 2016 Jul;
5(9):2180-9.
PMID: 27418384
Altered expression of TIP30, a tumor suppressor, has been observed in many cancers. In this study, we have evaluated the expression of TIP30 in the tissues of 209 hepatocellular carcinomas...